Literature DB >> 35727320

Risk of acute kidney injury after contrast-enhanced computerized tomography: a systematic review and meta-analysis of 21 propensity score-matched cohort studies.

Mikal Obed1, Maria Magdalena Gabriel2, Eva Dumann3, Clara Vollmer Barbosa3, Karin Weißenborn2, Bernhard Magnus Wilhelm Schmidt3.   

Abstract

OBJECTIVES: Intravenous application of contrast media is part of a wide spectrum of diagnostic procedures for better imaging quality. Clinical avoidance of contrast-enhanced imaging is an ever-present quandary in patients with impaired kidney function. The objective of this study was to estimate the risk for acute kidney injury (AKI), dialysis and mortality among patients undergoing contrast-enhanced CT compared to propensity score-matched controls (i.e. contrast-unenhanced CT). Selected cohort studies featured high-risk patients with advanced kidney disease and critical illness.
METHODS: This review was designed to conform to the Preferred Reporting Items in Systematic Reviews and Meta-Analysis (PRISMA) guidelines. PubMed was searched from August 2021 to November 2021 for all-language articles without date restriction. A random-effects model (DerSimonian and Laird method) was used for meta-analysis.
RESULTS: Twenty-one articles were included, comprising data of 169,455 patients. The overall risk of AKI was similar in the contrast-enhanced and unenhanced groups (OR: 0.97 [95% CI: 0.85; 1.11], p = 0.64), regardless of baseline renal function and underlying disease. Substantial heterogeneity was detected (I2 = 90%, p ≤ 0.0001). Multivariable logistic regression identified hypertension (p = 0.03) and estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 (p = 0.0001) as factors associated with greater risk of post-contrast AKI.
CONCLUSIONS: Based on propensity score-matched pairs obtained from 21 cohort studies, we found no evidence for increased risk for AKI, dialysis or mortality after contrast-enhanced CT among patients with eGFR ≥ 45 mL/min/1.73 m2. In congruence with the emerging evidence in the literature, caution should be exercised in patients with hypertension and eGFR ≤ 30 mL/min/1.73 m2. KEY POINTS: • The application of contrast media for medical imaging is not associated with higher odds for AKI, induction of renal replacement therapy, or mortality. Many comorbidities traditionally associated with greater risk for acute kidney injury do not appear to predispose for renal decline after contrast media exposure. • Underlying hypertension and eGFR less than or equal to 30 mL/min/1.73 m2 seem to predispose for post-contrast acute kidney injury. • Propensity score matching cannot account for unmeasured influences on AKI incidence, which needs to be addressed in the interpretation of results.
© 2022. The Author(s).

Entities:  

Keywords:  Acute kidney injury; Computed tomography; Contrast media; Glomerular filtration rate; Propensity score matching

Year:  2022        PMID: 35727320     DOI: 10.1007/s00330-022-08916-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  48 in total

1.  Acute anuria following intravenous pyelography in a patient with myelomatosis.

Authors:  E D BARTELS; G C BRUN; A GAMMELTOFT; P A GJØRUP
Journal:  Acta Med Scand       Date:  1954

2.  The effect of acute renal failure on mortality. A cohort analysis.

Authors:  E M Levy; C M Viscoli; R I Horwitz
Journal:  JAMA       Date:  1996-05-15       Impact factor: 56.272

3.  Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.

Authors:  Konstantinos Spargias; Elias Alexopoulos; Stamatis Kyrzopoulos; Panayiotis Iokovis; Panayiotis Iacovis; Darren C Greenwood; Athanassios Manginas; Vassilis Voudris; Gregory Pavlides; Christopher E Buller; Dimitrios Kremastinos; Dennis V Cokkinos
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

4.  Prevention of contrast-induced nephropathy: a single center randomized study.

Authors:  Diego Castini; Stefano Lucreziotti; Laura Bosotti; Diego Salerno Uriarte; Carlo Sponzilli; Alessandro Verzoni; Federico Lombardi
Journal:  Clin Cardiol       Date:  2010-03       Impact factor: 2.882

5.  Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting.

Authors:  Alice M Mitchell; Alan E Jones; James A Tumlin; Jeffrey A Kline
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

Review 6.  Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology.

Authors:  Stanley Goldfarb; Peter A McCullough; John McDermott; Spencer B Gay
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

Review 7.  Statistical primer: propensity score matching and its alternatives.

Authors:  Umberto Benedetto; Stuart J Head; Gianni D Angelini; Eugene H Blackstone
Journal:  Eur J Cardiothorac Surg       Date:  2018-06-01       Impact factor: 4.191

Review 8.  Post-contrast acute kidney injury - Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Aart J van der Molen; Peter Reimer; Ilona A Dekkers; Georg Bongartz; Marie-France Bellin; Michele Bertolotto; Olivier Clement; Gertraud Heinz-Peer; Fulvio Stacul; Judith A W Webb; Henrik S Thomsen
Journal:  Eur Radiol       Date:  2018-02-09       Impact factor: 5.315

9.  Effectiveness of contrast-associated acute kidney injury prevention methods; a systematic review and network meta-analysis.

Authors:  Khalid Ahmed; Terri McVeigh; Raminta Cerneviciute; Sara Mohamed; Mohammad Tubassam; Mohammad Karim; Stewart Walsh
Journal:  BMC Nephrol       Date:  2018-11-13       Impact factor: 2.388

Review 10.  Contrast-induced Nephropathy.

Authors:  Nazar M A Mohammed; Ahmed Mahfouz; Katafan Achkar; Ihsan M Rafie; Rachel Hajar
Journal:  Heart Views       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.